Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coli isolates with characterized resistance phenotypes

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 8, 2015, Pages 2306-2310

  Díez Aguilar, María ^a,b   Morosini, María Isabel ^a,b   López Cerero, Lorena ^b,c   Pascual, Álvaro ^b,c   Calvo, Jorge ^b,d   Martínez Martínez, Luis ^b,d,e   Marco, Francesc ^b,f   Vila, Jordi ^b,f   Ortega, Adriana ^b,g   Oteo, Jesús ^b,g   Cantón, Rafael ^a,b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e UNIVERSITY OF CANTABRIA   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Amoxicillin clavulanate; E. coli; MICs

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; DRUG SENSITIVITY; ESCHERICHIA COLI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; COMPARATIVE STUDY; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE;

EID: 84939475430     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv088     Document Type: Article

References (20)

1. Leverstein-van Hall MA, Waar K, Muilwijk J et al. Consequences of switching from a fixed 2:1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli. J Antimicrob Chemother 2013; 68: 2636-40.
2. Mimica Matanovic S, Bergman U, Vukovic D et al. Impact of restricted amoxicillin/clavulanic acid use on Escherichia coli resistance-antibiotic DU90% profiles with bacterial resistance rates: a visual presentation. Int J Antimicrob Agents 2010; 36: 369-73.
3. Oteo J, Campos J, Lázaro E et al. Increased amoxicillin-clavulanic acid resistance in Escherichia coli blood isolates, Spain. Emerg Infect Dis 2008; 14: 1259-62.
4. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 4.0. www.eucast.org/clinical_breakpoints.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
6. Nguyen HM, Labreche MJ, Grabrer CJ. Making sense of cephalosporin and amoxicillin/clavulanate susceptibility testing for uropathogens. Clin Infect Dis 2014; 59: 1349-50.
7. International Organization for Standardization (ISO). Clinical Laboratory Testing and In Vitro Diagnostic Test Systems-Susceptibility Testing of Infectious Agents and Evaluation of Performance of Antimicrobial Susceptibility Test Devices. Part 1: Reference Method for Testing the In Vitro Activity of Antimicrobial Agents against Rapidly Growing Aerobic Bacteria Involved in Infectious Diseases. International Standard 20776-1. Geneva: ISO, 2006.
8. Oteo J, González-López JJ, Ortega A et al. Inhibitor-resistant TEM-and OXA-1-producing Escherichia coli isolates resistant to amoxicillinclavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates. Antimicrob Agents Chemother 2014; 58: 3874-81.
9. Díaz MA, Hernández-Bello JR, Rodríguez-Baño J et al. Diversity of Escherichia coli strains producing extended-spectrum β-lactamases in Spain: second nationwide study. J Clin Microbiol 2010; 48: 2840-5.
10. Clark RB, Lewinski MA, Loeffelholz MJ et al. Cumitech 31A, Verification and Validation of Procedures in the Clinical Microbiology Laboratory. Sharp SE, coordinating ed. Washington, DC: ASM Press, 2009.
11. Greenwood D, O'Grady F, Baker P. An in vitro evaluation of clavulanic acid, a potent, broad-spectrum β-lactamase inhibitor. J Antimicrob Chemother 1979; 5: 539-47.
12. Jackson D, Cooper DL, Hardy TL et al. Pharmacokinetic, toxicological and metabolic studies with Augmentin. In: Rolinson GN, Watson A, eds. Augmentin: Clavulanate-Potentiated Amoxicillin. Proceedings of the First Symposium, 3 and 4 July 1980. Oxford: Excerpta Medica, 1980; 87-111.
13. Todd PA, Benfield P. Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1990; 39: 264-307.
14. Van der Bij AK, van Dijk K, Muilwijk J et al. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia. Clin Microbiol Infect 2012; 18: E466-72.
15. Hombach M, Bloemberg GV, Böttger EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J Antimicrob Chemother 2012; 67: 622-32.
16. Brown D, Cantón R, Dubreuil L et al. Widespread implementation of EUCAST breakpoints for antibacterial susceptibility testing in Europe. Euro Surveill 2015; 20: pii=21008.
17. Ortega A, Oteo J, Aranzamendi-Zaldumbide M et al. Spanish multicenter study of the epidemiology and mechanisms of amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob Agents Chemother 2012; 56: 3576-81.
18. Oliver A, Pérez-Vázquez M, Martínez-Ferrer M et al. Ampicillinsulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different β-lactam resistance phenotypes. Antimicrob Agents Chemother 1999; 43: 862-7.
19. Haeseker M, Havenith T, Stolk L et al. Is the standard dose of amoxicillin-clavulanic acid sufficient? BMC Pharmacol Toxicol 2014; 15: 38.
20. Rodríguez-Baño J, Navarro MD, Retamar P et al. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extendedspectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012; 54: 167-74.